Personalised treatment plans pair medication with unlimited Care Team support, nutrition and lifestyle guidance, and Canadian medical expertise, starting at $149/month Hims & Hers Health, Inc. (NYSE: ...
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers’ first ...
Direct-to-consumer virtual care company Hims & Hers announced it has signed an agreement to acquire international digital health company Eucalyptus in a deal worth up to $1.15 billion. Eucalyptus is a ...
Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Hims & Hers Health (HIMS) reported Q1 2026 earnings on May 11 and the stock dropped. Revenue of $608.1 million missed the $616.9 million estimate. The GAAP loss came in at $0.40 per share, far below ...
Zacks Investment Research on MSN
Hims & Hers Expands AI-Driven Personalized and Subscription-Based Care
The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has built a business model centered on personalized, subscription-based care that prioritizes convenience, accessibility and ...
Hims & Hers earnings Q2 2026 produced a $753M revenue beat but an $86.3M GAAP net loss, driven by $62.5M in FTC legal ...
Hims & Hers Health, Inc. HIMS is scheduled to report second-quarter 2026 results on Aug. 10, after the closing bell. In the last reported quarter, the company’s loss per share of 18 cents lagged the ...
Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform for eligible customers in Canada. This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results